OSLO, NORWAY – 24 August 2021: Genetic Analysis AS (“GA” or “the Company”) hereby announces that the Company has received preliminary approval for listing on Spotlight Stock Market (“Spotlight”). The Company hereby also publishes prospectus in connection with planned initial public offering of units, which initially amounts to a maximum of approximately NOK 60.1 million (the “IPO”) and further a maximum of approximately NOK 43 million and NOK 57.7 million, before issue costs, through warrant exercise of TO 1 and TO 2. The subscription period for the IPO begins on Monday, 30 August 2021 and ends on 13 September 2021. GA has in advance agreed to approximately 80.4 percent of the initial part of the IPO through written subscription commitments from existing shareholders and external cornerstone investors. The prospectus is available via the Company’s (www.genetic-analysis.com), Sedermera Fondkommission’s (www.sedermera.se) and Spotlight Stock Market’s (www.spotlightstockmarket.com) respective web pages. Nordnet Bank AB is acting Selling Agent in the IPO.
Spotlight’s decision is conditional, among other things, on GA meeting the ownership distribution requirement and that the Company is provided with sufficient capital to cover the working capital requirement for the next twelve months.